• Dapps:16.23K
  • Blockchains:78
  • Active users:66.47M
  • 30d volume:$303.26B
  • 30d transactions:$879.24M

HBAR Growth Forecast: Opportunities for Traders and Enterprises

user avatar

by Giorgi Kostiuk

a year ago


Hedera Hashgraph's HBAR token is gaining attention, showing potential for new heights. Crypto analyst Rose suggests recent consolidation signals possible growth.

HBAR’s Technical Signals

HBAR dropped by 52.30% over the past 27 days, but a quick turnaround is expected, with a potential 141.23% increase over 17 days. The current price may reach $0.44619 by January 21, 2025. HBAR holds its position above the 0.786 Fibonacci level, indicating likely upward movement.

Google Cloud Partnership as a Growth Pathway

Speculation mounts about a potential integration with Google Cloud, which could bolster HBAR's position among enterprise blockchain solutions. This could attract institutional users seeking reliable blockchain solutions. Such partnership activity could pave new opportunities for large-scale adoption.

Positive Sentiment and Growth Analysis

Analyst Rose, known for accurate forecasts, points to the mix of technical and fundamental factors driving HBAR's growth potential. Increased market interest in the token makes it an attractive opportunity for traders, particularly with potential new partnerships.

HBAR shows potential for significant growth due to technical consolidation and market interest driven by potential new partnerships. This makes the token attractive to investors seeking high returns.

0

Rewards

chest
chest
chest
chest

More rewards

Discover enhanced rewards on our social media.

chest

Other news

Disney's $1 Billion Investment in OpenAI Marks a New Era in Entertainment

chest

The Walt Disney Company has announced a groundbreaking $1 billion equity investment in OpenAI, marking a significant partnership to enhance AI-driven storytelling in entertainment.

user avatarElias Mukuru

Rezolute, Inc. Shares Plummet 90% Following Disappointing Clinical Trial Results

chest

Rezolute, Inc. shares dropped 90% after disappointing Phase 3 clinical trial results for the therapy ersodetug.

user avatarDiego Alvarez

Rezolute Plans FDA Discussions Despite Clinical Trial Setback

chest

Rezolute plans to meet with the FDA to discuss next steps for ersodetug development following disappointing Phase 3 trial results.

user avatarKenji Takahashi

Nexo Faces Regulatory Challenges in South America

chest

Nexo must navigate complex regulatory landscapes in South America to establish its services.

user avatarMiguel Rodriguez

Nexo Acquires Buenbit to Expand in South America

chest

Nexo has acquired Argentine fintech Buenbit, marking a significant expansion into the South American crypto market.

user avatarGustavo Mendoza

Matthew Perry Remains Confident in JasmyCoin's Long-Term Potential

chest

Matthew Perry remains confident in JasmyCoin's long-term potential despite recent price drops.

user avatarRajesh Kumar

Important disclaimer: The information presented on the Dapp.Expert portal is intended solely for informational purposes and does not constitute an investment recommendation or a guide to action in the field of cryptocurrencies. The Dapp.Expert team is not responsible for any potential losses or missed profits associated with the use of materials published on the site. Before making investment decisions in cryptocurrencies, we recommend consulting a qualified financial advisor.